Jardiance vs Lantus: Long-Term Durability of Blood Sugar Control

How Each Drug Controls Blood Sugar Over Time

Empagliflozin blocks the sodium-glucose cotransporter-2 (SGLT2) in the kidney proximal tubule, forcing roughly 60 to 90 g of glucose into the urine each day. Insulin glargine replaces or supplements endogenous basal insulin, suppressing hepatic glucose output overnight and between meals. These two mechanisms create different glycemic trajectories over a 3-to-5-year horizon.

Empagliflozin's Glycemic Durability

The EMPA-REG OUTCOME trial followed 7,020 adults with type 2 diabetes and established cardiovascular disease for a median of 3.1 years [1]. The empagliflozin group (pooled 10 mg and 25 mg) maintained an HbA1c separation from placebo of approximately 0.4 percentage points across the entire observation window, without meaningful attenuation over time on trial.

Outside that placebo-controlled context, open-label extension data and real-world registries show a more modest long-term picture. A 2019 analysis in Diabetes Care (N=4,347 U.S. Claims) found that SGLT2 inhibitors produced a mean HbA1c reduction of 0.76% at 6 months, with roughly 30% of that effect dissipating by 36 months as patients' beta-cell function continued to decline naturally [2].

The key caveat: empagliflozin's glucose-lowering mechanism depends entirely on filtered glucose load. When eGFR drops below 45 mL/min/1.73m², the glycemic contribution shrinks substantially, though cardiorenal benefits persist down to eGFR 20 per the 2023 ADA Standards of Care [3].

Insulin Glargine's Glycemic Durability

Insulin glargine has no renal threshold for glycemic efficacy. Titrate the dose and the glucose comes down. That is why ORIGIN (N=12,537, median 6.2 years) was able to sustain median fasting glucose near 5.3 mmol/L in the glargine arm throughout the trial by allowing dose escalation from a mean of 11.6 U/day at baseline to 26.4 U/day at year 6 [4].

The durability trade-off is weight gain and dose creep. The ORIGIN glargine arm gained a mean of 1.6 kg above the standard-care arm over 6.2 years. Hypoglycemia (any episode) occurred in 28.5% of glargine-treated patients vs 6.7% with standard care [4]. Dose escalation to maintain targets is not a failure of the drug, but it does require ongoing titration effort from patients and clinicians.

Comparing the Two Trajectories

Empagliflozin delivers a moderate, relatively flat glycemic effect without dose adjustment, but cannot overcome progressive beta-cell failure alone. Insulin glargine can theoretically match any glycemic target if the dose is titrated correctly, at the cost of weight and hypoglycemia risk. The practical durability question is not just "does HbA1c stay down" but also "what does the patient look like 5 years from now."

Cardiovascular Outcomes: Where the Evidence Diverges Most

This is the section where Jardiance and Lantus tell completely different stories. The contrast matters clinically and is now embedded in major guidelines.

EMPA-REG OUTCOME: A Cardiovascular Signal, Not Just Glucose

EMPA-REG OUTCOME (N=7,020, median 3.1 years, published NEJM 2015) was a superiority trial, not just a non-inferiority safety study [1]. Compared to placebo added to standard care:

• 3-point MACE: empagliflozin reduced events by 14% (HR 0.86, 95% CI 0.74 to 0.99, P=0.04 for superiority)
• CV death: reduced by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001)
• Hospitalization for heart failure: reduced by 35% (HR 0.65, 95% CI 0.50 to 0.85, P=0.002)
• All-cause mortality: reduced by 32% (HR 0.68, 95% CI 0.57 to 0.82, P<0.001)

These were absolute risk reductions of clinical magnitude, not just statistical artifacts. The benefit appeared early (within 3 months for HHF) and was maintained.

ORIGIN: Cardiovascular Neutrality

ORIGIN (N=12,537, median 6.2 years, published NEJM 2012) tested whether early basal insulin initiation in dysglycemia (pre-diabetes, IFG, or early T2D) would reduce CV events [4]. Insulin glargine did not increase CV events (HR for MACE 1.02, 95% CI 0.94 to 1.11), establishing long-term CV safety. It did not, however, demonstrate superiority over standard care on any CV outcome.

The populations differ: EMPA-REG enrolled patients with established CVD; ORIGIN enrolled an earlier-stage population. Still, the 2024 ADA Standards of Care explicitly recommend an SGLT2 inhibitor with proven CV benefit for patients with T2D and established ASCVD or high CV risk, independent of HbA1c level [3].

What the Guidelines Say

The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Diabetes Management Algorithm states: "In patients with T2D and established ASCVD, heart failure, or CKD, an SGLT2i or GLP-1 RA with proven CV benefit should be prioritized regardless of baseline A1C or the need for additional glucose lowering." [5]

Insulin glargine enters the algorithm at a later stage, typically when HbA1c remains above 10% despite oral and injectable non-insulin therapy, when symptomatic hyperglycemia is present, or when C-peptide testing suggests significant insulin deficiency.

Hypoglycemia Risk Over the Long Term

Hypoglycemia is not merely uncomfortable. Severe episodes are associated with a 1.8-fold increase in CV event risk and a 2.1-fold increase in dementia risk in older adults, per a 2019 meta-analysis in Diabetes Care (19 studies, N=approximately 900,000 patient-years) [6].

Empagliflozin's Low Hypoglycemia Profile

Because empagliflozin's glucose excretion scales with the blood glucose concentration, the drug self-limits. At euglycemia, the kidney reabsorbs glucose normally and little additional excretion occurs. In EMPA-REG OUTCOME, confirmed hypoglycemia (plasma glucose <70 mg/dL) occurred in 7.7% of the empagliflozin group vs 9.1% placebo, with most events attributable to background sulfonylurea use rather than empagliflozin itself [1].

Insulin Glargine and Titration-Dependent Hypoglycemia

Insulin glargine's hypoglycemia risk scales with dose and with how close to target the fasting glucose is pushed. In ORIGIN, any hypoglycemia occurred in 28.5% of glargine patients over 6.2 years, with severe hypoglycemia (requiring assistance) in 1.00 per 100 patient-years vs 0.31 for standard care [4]. Nocturnal hypoglycemia is the dominant pattern because glargine's peakless profile does not protect against overnight drift when the dose is too high.

Weight Trajectories: A 5-Year View

Weight matters for durability of glycemic control because adiposity drives insulin resistance. A drug that lowers HbA1c but adds 3 to 5 kg of fat mass may be eroding its own benefit over time.

Empagliflozin and Sustained Weight Loss

In EMPA-REG OUTCOME, empagliflozin produced a mean weight reduction of 2.0 kg (95% CI minus 2.2 to minus 1.7) relative to placebo at week 12, and this loss was maintained across 3.1 years of follow-up [1]. The mechanism is caloric loss through glucosuria (roughly 240 kcal/day at maximal effect) combined with mild osmotic diuresis that reduces plasma volume.

Insulin Glargine and Progressive Weight Gain

In ORIGIN, the glargine group gained 1.6 kg more than standard care at 6 years [4]. Weight gain with basal insulin is well-characterized: it is partly explained by the anabolic effect of insulin, partly by reduced glucosuria, and partly by defensive eating in response to hypoglycemia. Each kilogram of weight gain can raise insulin requirements by approximately 0.04 U/kg/day, creating a reinforcing cycle.

Renal Function and Durability of Effect

Both drugs interact with renal function, but in opposite ways relative to glycemic efficacy.

Empagliflozin: Glycemic Effect Requires Adequate GFR

Empagliflozin's glucose-lowering depends on sufficient filtered glucose load. At eGFR 45 to 59 mL/min/1.73m², the HbA1c reduction is blunted to roughly 0.3 to 0.4%. Below eGFR 45, the FDA label for Jardiance states the drug should not be used for glycemic control (though it may continue for CV or renal indications) [7]. This is a real long-term durability ceiling for patients with progressive CKD.

Insulin Glargine: Caution With Low GFR, Not a Barrier

Insulin glargine's pharmacokinetics are not significantly altered by CKD stage 1 to 3. At eGFR <30, insulin clearance decreases and the effective half-life extends, which increases hypoglycemia risk and requires dose reduction, but the drug continues to lower glucose. For patients on hemodialysis, insulin remains the standard glucose-lowering agent.

When to Switch From Jardiance to Lantus (or Add It)

Switching from empagliflozin to insulin glargine is rarely the right move. Adding insulin glargine on top of empagliflozin is common and rational. Here are the specific clinical scenarios that push a prescriber toward basal insulin.

Scenarios That Favor Moving to or Adding Lantus

1. HbA1c above 10% with symptoms. Empagliflozin cannot lower HbA1c by 2 to 3 percentage points alone. Insulin glargine can, especially when titrated to a fasting target of 80 to 110 mg/dL.
2. eGFR falls below 45 mL/min/1.73m². Empagliflozin loses glycemic potency. Insulin glargine remains effective (with dose adjustment).
3. Type 1 diabetes diagnosis confirmed. Empagliflozin is not FDA-approved for T1D and carries a disproportionately high risk of euglycemic diabetic ketoacidosis in absolute insulin deficiency states [7].
4. Pregnancy. Insulin glargine is the preferred basal insulin in pregnancy (category B data, well-characterized safety profile). Empagliflozin crosses the placenta and is contraindicated in the second and third trimesters [7].
5. Recurrent DKA or severe hyperglycemia on oral therapy. Insulin replacement addresses the root cause; SGLT2 inhibitors do not.
6. Acute illness or surgical admission. Empagliflozin should be held 3 to 5 days before procedures with NPO requirements. Insulin glargine can continue with adjusted dosing.

Scenarios Where Empagliflozin Should Stay in the Regimen

If a patient with T2D and heart failure or ASCVD has their Jardiance discontinued solely because HbA1c is not at goal, this represents an evidence-based opportunity cost. The cardiorenal benefits of empagliflozin persist even when its glycemic contribution is modest. Adding insulin glargine to empagliflozin is preferable to replacing it.

The HealthRX clinical team uses a three-question decision framework before any switch away from an SGLT2 inhibitor to basal insulin:

1. Does the patient have established CVD, HFrEF, or CKD? If yes, maintain empagliflozin unless contraindicated.
2. Is the HbA1c above 9% or is symptomatic hyperglycemia present? If yes, add insulin glargine rather than swap.
3. Is eGFR below 45 or is pregnancy confirmed? If yes, the switch to insulin glargine as primary agent is appropriate.

Practical Dosing and Titration Comparison

Empagliflozin Dosing

Empagliflozin is initiated at 10 mg once daily with or without food. The dose may be increased to 25 mg once daily for additional glycemic benefit if tolerated and eGFR is at or above 45 mL/min/1.73m² [7]. No titration based on glucose readings is required. The dose stays fixed once established.

Insulin Glargine Titration

Insulin glargine is typically started at 0.1 to 0.2 U/kg/day subcutaneously at bedtime (or 10 U fixed start for conservative initiation per the "10-2" ADA protocol). The dose is then self-titrated by the patient: increase by 2 units every 3 days if fasting glucose remains above 130 mg/dL, hold or reduce if fasting glucose drops below 80 mg/dL [3]. This titration cycle continues indefinitely, which requires patient engagement that empagliflozin does not.

Side-Effect Profiles That Affect Long-Term Adherence

Long-term durability of any drug also depends on whether patients stay on it.

Jardiance-Specific Risks

• Genital mycotic infections occur in 6 to 8% of women and 2 to 4% of men on SGLT2 inhibitors. Most respond to a single course of fluconazole, but recurrent infections are a common discontinuation reason [1].
• Urinary tract infections are moderately increased. Serious urosepsis is rare but has been reported.
• Euglycemic DKA is uncommon in T2D (estimated 0.16 per 1,000 patient-years) but requires awareness before surgery, prolonged fasting, or acute illness [7].
• Fournier's gangrene is a rare but serious infection of the perineal fascia. The FDA added a boxed warning in 2018 based on 12 postmarketing cases [7].
• Volume depletion manifests as dizziness or orthostatic hypotension, particularly in patients on loop diuretics or with baseline systolic BP <100 mmHg.

Lantus-Specific Risks

• Injection site reactions include lipohypertrophy (up to 30% in long-term users), which impairs absorption predictability.
• Nocturnal hypoglycemia. Even glargine's "peakless" profile allows for low overnight glucose when the dose overshoots.
• Weight gain. Addressed above. Averages 1 to 3 kg in the first year.
• Mitogenic concerns. A 2009 observational signal raised concern about insulin glargine and cancer risk; subsequent analysis of ORIGIN (6.2 years, N=12,537) found no increase in cancer incidence (HR 1.00, 95% CI 0.88 to 1.13) [4], effectively closing this question.

Cost and Access Considerations

Lantus (insulin glargine originator) has a list price of approximately $280, $325 per 10 mL vial in the U.S. As of 2024. The biosimilar Basaglar (insulin glargine-yfgn) and the interchangeable biosimilar Rezvoglar are available at 15 to 20% lower list price, and Eli Lilly's authorized generic list price is $35 per vial.

Jardiance carries a list price near $600, $650 per month for a 30-tablet supply. Patient assistance programs through Boehringer Ingelheim and Eli Lilly cover costs for eligible uninsured patients. The IRA insulin cost-sharing cap of $35/month for Medicare Part D beneficiaries applies to insulin products (including Lantus biosimilars) but not to empagliflozin.

For many Medicare patients, basal insulin ends up being substantially cheaper out-of-pocket than an SGLT2 inhibitor. Cost should be addressed explicitly at the prescribing decision point rather than after a patient quietly discontinues a $600/month drug.

Summary of Key Evidence at a Glance

| Feature | Empagliflozin (Jardiance) | Insulin Glargine (Lantus) | |---|---|---| | HbA1c reduction | 0.6 to 0.8% | 1.0 to 1.5% (titration-dependent) | | Weight | minus 2 to 3 kg | plus 1 to 3 kg | | CV mortality | minus 38% vs placebo (EMPA-REG) | Neutral vs standard care (ORIGIN) | | HHF reduction | minus 35% vs placebo (EMPA-REG) | Not demonstrated | | Hypoglycemia | Low | Moderate | | eGFR <45 | Glycemic efficacy lost | Requires dose reduction, still works | | Oral vs injectable | Oral once daily | Subcutaneous once daily | | Renal protection | Yes (independent of glucose) | Not demonstrated |